Acumen Pharmaceuticals, Inc.
ABOS
$2.99
-$0.18-5.54%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 68.70% | 125.82% | |||
| Gross Profit | -68.70% | -125.82% | |||
| SG&A Expenses | 1.76% | -0.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 53.94% | -16.07% | |||
| Operating Income | -53.94% | 16.07% | |||
| Income Before Tax | -57.78% | 17.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -57.78% | 17.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -57.78% | 17.51% | |||
| EBIT | -53.94% | 16.07% | |||
| EBITDA | -53.97% | 16.08% | |||
| EPS Basic | -38.05% | 20.96% | |||
| Normalized Basic EPS | -38.05% | 20.97% | |||
| EPS Diluted | -38.05% | 20.96% | |||
| Normalized Diluted EPS | -38.05% | 20.97% | |||
| Average Basic Shares Outstanding | 14.29% | 4.37% | |||
| Average Diluted Shares Outstanding | 14.29% | 4.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||